- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Insights on Allogeneic Hematopoietic Cell Transplantation: Values of Older Adult Patients
Sikander Ailawadhi, MD, discusses how the 2024 ASH Annual Meeting’'s study on “"Hematologists’' Approach to Discussing Older Patients’ Values in the Context of Allogeneic Hematopoietic Cell Transplantation”" explored the methodologies hematologists use to engage older patients in treatment decisions, highlighting key findings related to patient values and the importance of incorporating these factors into transplant decision-making for improved patient-centered care.
EP: 1.Unmet Needs and Emerging Trends in Hematologic Cancer Management Around ASH 2024
EP: 2.Insights on CLL and SLL Treatment with BTK Inhibitors: Patient Preferences and Shared Decision-Making
EP: 3.Insights on Multiple Myeloma Treatment: Real-World Data on Survivorship Burden and Patient Preferences
EP: 4.Insights on Allogeneic Hematopoietic Cell Transplantation: Values of Older Adult Patients
EP: 5.Advancing Hematologic Care and the Future of Shared Decision-Making
Video content above is prompted by the following:
- Discuss the data that was were presented at the 2024 ASH Annual Meeting titled in “Hematologists’ Approach to Discussing Older Patients’ Values in the Context of Allogeneic Hematopoietic Cell Transplantation.”
- What was the objective of the study?
- How was this study designed/what methodology was used?
- What results were presented?
Long-Term Data Show Favorable Survival Outcomes With G-Clb in Treatment-Naive CLL
May 1st 2025Participants in the CLL11 trial and a smaller group of patients followed after study completion showed improved overall survival with obinutuzumab and chlorambucil (G-Clb) compared with chemotherapy plus rituximab or chemotherapy alone for chronic lymphocytic leukemia (CLL).
Read More
Acalabrutinib Combos Improve PFS vs CIT in First-Line CLL
April 20th 2025Acalabrutnib plus venetoclax, with or without obinutuzumab, improved progression-free survival (PFS) compared with chemoimmunotherapy (CIT) in patients with untreated chronic lymphocytic leukemia (CLL), meeting the phase 3 AMPLIFY study’s primary endpoint.
Read More
